Global Influenza Diagnostics Market Growth, Share, Size, Trends and Forecast (2025 - 2031)

• February 2021, Becton, Dickinson and Company (US) received emergency use authorization (EUA) from the FDA for a new molecular diagnostic test that detects both SARS-CoV-2 and influenza A+B.
• March 2021, Abbott Laboratories, Inc. (US) received emergency use authorization (EUA) from the FDA for a laboratory PCR assay that detects and differentiates SARS-CoV-2, flu A, flu B, and RSV in a single test.
• May 2021, Becton, Dickinson and Company (US) received FDA approval for the BD Veritor Plus System, which detects SARS-CoV-2, influenza A, and influenza B.

In this report, the Influenza Diagnostics Market has been segmented by Test Type, Molecular, End Users and Geography.

Influenza Diagnostics Market, Segmentation by Test Type

The Influenza Diagnostics Market has been segmented by Test Type into Traditional Diagnostic Test and Molecular Diagnostic Assay.

Traditional Diagnostic Test

Traditional diagnostic tests, notably Rapid Influenza Diagnostic Tests (RIDTs), remain a cornerstone in the influenza diagnostics market, capturing around 66.70% of the global share in 2024. Their popularity stems from their rapid turnaround times and cost-effectiveness, making them suitable for widespread use in various healthcare settings. However, the relatively lower sensitivity of these tests compared to molecular assays has prompted a shift towards more accurate diagnostic solutions.

Molecular Diagnostic Assay

Molecular diagnostic assays, including RT-PCR and Loop-Mediated Isothermal Amplification (LAMP), are increasingly favored for their superior sensitivity and specificity in detecting influenza viruses. Holding approximately 33.30% of the market share in 2024, this segment is experiencing robust growth driven by the need for precise and rapid diagnostics. The integration of molecular assays in point-of-care testing is further enhancing their adoption, offering reliable results that facilitate timely clinical decisions.

Influenza Diagnostics Market, Segmentation by Molecular

The Influenza Diagnostics Market has been segmented by Molecular into PCR, INAAT- NASBAT, TMABAS

Polymerase Chain Reaction (PCR)

Polymerase Chain Reaction (PCR) is a widely utilized molecular diagnostic technique in the influenza diagnostics market. In 2022, the RT-PCR segment held a significant share of 21.8% in the U.S. market. PCR offers high sensitivity and specificity, delivering results faster compared to traditional methods like cell culture. Advancements in PCR technology, including real-time PCR systems, have further enhanced its efficiency and accuracy.

Nucleic Acid Sequence-Based Amplification (NASBA)

NASBA is an isothermal amplification technique primarily used for amplifying single-stranded RNA, making it suitable for detecting RNA viruses like influenza. Unlike PCR, NASBA operates at a constant temperature, eliminating the need for thermal cycling. This method offers rapid and sensitive detection, making it valuable for point-of-care testing, especially in resource-limited settings.

Transcription-Mediated Amplification-Based Assay (TMABA)

Transcription-Mediated Amplification (TMA) is another isothermal nucleic acid amplification method used in influenza diagnostics. TMA amplifies RNA targets at a constant temperature, providing rapid and sensitive detection. Its high-throughput capability makes it suitable for large-scale screening and surveillance programs.

Influenza Diagnostics Market, Segmentation by End Users

The Influenza Diagnostics Market has been segmented by End Users into Hospital, Research Laboratory and Other End Users.

Hospitals

Hospitals dominate the influenza diagnostics market, holding approximately 54.40% of the global share in 2024. This leadership is driven by the high influx of patients during flu seasons and the critical need for prompt and accurate diagnostic testing to manage treatment and prevent outbreaks. The presence of centralized laboratories with advanced diagnostic equipment in hospitals enhances their capacity to conduct efficient and large-scale testing.

Research Laboratories

Research laboratories are pivotal in the innovation and refinement of influenza diagnostic methods. Through extensive research and clinical trials, these institutions contribute to the development of more accurate and rapid diagnostic tools. Their efforts are essential in understanding the evolving nature of influenza viruses and improving diagnostic responses.

Other End Users

Encompassing diagnostic laboratories, point-of-care testing centers, and home healthcare services, this segment plays a significant role in the influenza diagnostics market. Diagnostic laboratories, in particular, have seen substantial growth due to the increasing need for rapid and reliable testing. The expansion of point-of-care testing and home healthcare options further enhances the accessibility and convenience of influenza diagnostics for a broader population.

Influenza Diagnostics Market, Segmentation by Geography

In this report, the Influenza Diagnostics Market has been segmented by Geography into five regions; North America, Europe, Asia Pacific, Middle East and Africa and Latin America.

Influenza Diagnostics Market Share (%), by Geographical Region

North America

North America dominates the global influenza diagnostics market, capturing approximately 37.20% of the revenue share in 2024. This leadership is attributed to the region's advanced healthcare infrastructure, significant investments in research and development, and the widespread use of rapid diagnostic tests. The United States, in particular, plays a pivotal role, emphasizing proactive influenza surveillance and control measures.

Europe

Europe maintains a strong position in the influenza diagnostics market, supported by its comprehensive healthcare systems and a heightened focus on early disease detection. The region's commitment to preventive healthcare and the presence of leading diagnostic companies contribute to its sustained market presence. Countries such as Germany, France, and the UK are at the forefront, utilizing advanced diagnostic technologies to effectively manage influenza outbreaks.

Asia Pacific

The Asia Pacific region is witnessing significant growth in the influenza diagnostics market, with a projected CAGR of 6.65% from 2024 to 2032. This expansion is driven by increasing healthcare investments, heightened awareness of infectious diseases, and governmental initiatives aimed at enhancing public health infrastructure. Nations like China, India, and Japan are actively adopting advanced diagnostic tools to improve influenza detection and management.

Middle East and Africa

The Middle East and Africa region is gradually expanding its presence in the influenza diagnostics market, propelled by the rising prevalence of influenza and the adoption of modern diagnostic technologies. Efforts to bolster healthcare infrastructure and increased governmental focus on infectious disease control are key factors contributing to market growth in this area.

Latin America

Latin America is emerging as a notable contributor to the influenza diagnostics market, with countries like Brazil and Mexico leading regional advancements. The market's growth is fueled by heightened awareness of influenza prevention, the expansion of healthcare services, and the integration of rapid diagnostic tests to effectively manage seasonal outbreaks.

This report provides an in depth analysis of various factors that impact the dynamics of Global Influenza Diagnostics Market. These factors include; Market Drivers, Restraints and Opportunities Analysis.

Drivers

• Technological advancements spur growth
• Rising prevalence demands diagnostics
• Increasing healthcare expenditure supports
• Growing awareness boosts demand

• Pandemic preparedness drives innovation: The global influenza diagnostics market has experienced significant growth, driven largely by the pressing need for pandemic preparedness. With outbreaks like the H1N1 influenza pandemic of 2009 and the more recent COVID-19 pandemic, there has been a heightened awareness of the importance of early detection and rapid response to infectious diseases. This awareness has fueled innovation in influenza diagnostics, leading to the development of advanced testing methods such as nucleic acid amplification tests (NAATs), rapid influenza diagnostic tests (RIDTs), and next-generation sequencing (NGS) technologies. These innovations not only enable healthcare providers to accurately diagnose influenza infections but also facilitate surveillance efforts to monitor the spread of the virus and inform public health interventions.

  The increasing adoption of point-of-care testing (POCT) solutions has contributed to the growth of the influenza diagnostics market. POCT devices offer the advantage of delivering rapid results, allowing for timely clinical decision-making and patient management. Moreover, advancements in technology have led to the development of more accurate and sensitive diagnostic assays, enhancing the reliability of influenza testing. As governments and healthcare organizations worldwide recognize the importance of preparedness for potential influenza pandemics, the demand for innovative diagnostic solutions is expected to continue driving growth in the global influenza diagnostics market.

Restraints

• High cost limits accessibility
• Regulatory hurdles constrain development
• Limited healthcare infrastructure hampers
• Lack of skilled personnel impedes

• Emerging market challenges persist: Emerging markets continue to grapple with a myriad of challenges, from economic volatility to political instability and infrastructural limitations. These factors significantly impact the healthcare sector, particularly in the realm of diagnostics. The global influenza diagnostics market reflects this complexity, as emerging economies struggle to adopt advanced diagnostic technologies due to cost constraints and inadequate healthcare infrastructure. Additionally, the high variability of influenza strains poses a continuous challenge for diagnostics development and deployment in these regions, further exacerbating the issue.

  Despite these challenges, the global influenza diagnostics market is witnessing steady growth, driven by increasing awareness about the importance of early detection and management of influenza outbreaks. Moreover, advancements in technology, such as the development of rapid diagnostic tests and molecular diagnostics, are gradually making inroads into emerging markets, albeit at a slower pace compared to developed economies. Collaborative efforts between governments, healthcare organizations, and international agencies are crucial in addressing the unique challenges faced by emerging markets in influenza diagnostics, thereby improving healthcare outcomes and mitigating the impact of influenza outbreaks.

Opportunities

• Expanded point-of-care testing
• Innovations in molecular diagnostics
• Collaborations for novel solutions
• Rising demand for rapid tests

• Untapped potential in emerging markets: The global influenza diagnostics market holds significant untapped potential in emerging markets, driven by several factors. Firstly, the rising prevalence of influenza in these regions amplifies the demand for accurate and efficient diagnostic tools. Emerging economies often face challenges in healthcare infrastructure and disease surveillance, making rapid and reliable diagnostic solutions crucial for timely intervention and management. Secondly, advancements in diagnostic technologies, such as molecular diagnostics and point-of-care testing, offer opportunities for market expansion in these regions. These technologies enable faster and more accurate detection of influenza viruses, enhancing healthcare outcomes and reducing the burden on healthcare systems.

  Increasing investments in healthcare infrastructure and the growing awareness about the importance of early disease detection further fuel the growth of the influenza diagnostics market in emerging economies. Governments and healthcare organizations are increasingly focusing on preventive healthcare measures, including the adoption of advanced diagnostic tools, to mitigate the impact of influenza outbreaks. Additionally, strategic collaborations between diagnostic companies and local stakeholders facilitate market penetration and the development of tailored solutions to address the specific needs of emerging markets. Overall, the untapped potential in emerging markets presents lucrative opportunities for stakeholders in the global influenza diagnostics market to expand their presence and contribute to improved healthcare outcomes.

Key players in Global Influenza Diagnostics Market include:

• Abbott Laboratories
• Becton, Dickinson and Company
• Coris BioConcept
• DiaSorin SpA
• F. Hoffmann-La Roche Ltd
• Luminex Corporation
• Meridian Bioscience Inc.
• Quidel Corporation
• Sekisui Diagnostics
• Thermo Fisher Scientific Inc

In this report, the profile of each market player provides following information:

• Company Overview and Product Portfolio
• Key Developments
• Financial Overview
• Strategies
• Company SWOT Analysis